NAV

Sparfosic acid

Identification

Generic Name
Sparfosic acid
DrugBank Accession Number
DB03459
Background

Sparfosic acid is a solid. This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at the terminal nitrogen atom. This substance is known to target aspartate carbamoyltransferase catalytic chain and CAD protein.

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 255.1193
Monoisotopic: 255.014402813
Chemical Formula
C6H10NO8P
Synonyms
  • ácido esparfósico
  • Acidum sparfosicum
  • N-(phosphonacetyl)-L-aspartic acid
  • N-(phosphonoacetyl)-L-aspartic acid
  • N-phosphonacetyl-L-aspartic acid
  • PALA
  • phosphonoacetyl-L-aspartic acid
  • Sparfosic acid
External IDs
  • NCI 224131
  • NSC-224131
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UAspartate carbamoyltransferase catalytic chainNot AvailableShigella flexneri
UCAD proteinNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Sparfosic acid is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Sparfosic acid is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Sparfosic acid is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Sparfosic acid is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Sparfosic acid is combined with Bupivacaine.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aspartic acid and derivatives. These are compounds containing an aspartic acid or a derivative thereof resulting from reaction of aspartic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Aspartic acid and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Fatty acids and conjugates / Dicarboxylic acids and derivatives / Organic phosphonic acids / Secondary carboxylic acid amides / Carboxylic acids / Organopnictogen compounds / Organophosphorus compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Aliphatic acyclic compound / Aspartic acid or derivatives / Carbonyl group / Carboxamide group / Carboxylic acid / Dicarboxylic acid or derivatives / Fatty acid / Hydrocarbon derivative / N-acyl-alpha amino acid or derivatives / N-acyl-alpha-amino acid
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
78QVZ7RG8L
CAS number
51321-79-0
InChI Key
ZZKNRXZVGOYGJT-VKHMYHEASA-N
InChI
InChI=1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/t3-/m0/s1
IUPAC Name
(2S)-2-(2-phosphonoacetamido)butanedioic acid
SMILES
[H]N([C@@H](CC(O)=O)C(O)=O)C(=O)CP(O)(O)=O

References

General References
Not Available
PubChem Compound
39981
PubChem Substance
46507931
ChemSpider
36554
ChEMBL
CHEMBL504802
ZINC
ZINC000001563934
Therapeutic Targets Database
DNC000976
PDBe Ligand
PAL
PDB Entries
1acm / 1d09 / 1ekx / 1f1b / 1i5o / 1ml4 / 1q95 / 1tth / 1xjw / 3r7l …
show 14 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility6.73 mg/mLALOGPS
logP-2.1ALOGPS
logP-2.7Chemaxon
logS-1.6ALOGPS
pKa (Strongest Acidic)1.65Chemaxon
Physiological Charge-3Chemaxon
Hydrogen Acceptor Count8Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area161.23 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity46.97 m3·mol-1Chemaxon
Polarizability19.82 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9414
Blood Brain Barrier+0.8603
Caco-2 permeable-0.7034
P-glycoprotein substrateNon-substrate0.8445
P-glycoprotein inhibitor INon-inhibitor0.95
P-glycoprotein inhibitor IINon-inhibitor0.9947
Renal organic cation transporterNon-inhibitor0.9721
CYP450 2C9 substrateNon-substrate0.7884
CYP450 2D6 substrateNon-substrate0.8184
CYP450 3A4 substrateNon-substrate0.6647
CYP450 1A2 substrateNon-inhibitor0.8948
CYP450 2C9 inhibitorNon-inhibitor0.9332
CYP450 2D6 inhibitorNon-inhibitor0.9364
CYP450 2C19 inhibitorNon-inhibitor0.9108
CYP450 3A4 inhibitorNon-inhibitor0.9391
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9952
Ames testNon AMES toxic0.6868
CarcinogenicityNon-carcinogens0.8411
BiodegradationReady biodegradable0.8331
Rat acute toxicity2.0339 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9753
hERG inhibition (predictor II)Non-inhibitor0.9733
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00dr-5940000000-c0436e3ff5b46958d6ce
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03xu-0910000000-47e825a932681966ae47
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01qi-2920000000-89a942fd76e70caca104
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-1900000000-cda56d0dfb864f4ea8ff
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-9400000000-45a350ac20f1f6cf81e0
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0080-9300000000-37ac7a7eabec7bc29177
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-005i-9100000000-3918828fee3f1d6cecfa
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-155.9763663
predicted
DarkChem Lite v0.1.0
[M-H]-144.06929
predicted
DeepCCS 1.0 (2019)
[M+H]+154.3221663
predicted
DarkChem Lite v0.1.0
[M+H]+146.46486
predicted
DeepCCS 1.0 (2019)
[M+Na]+155.1208663
predicted
DarkChem Lite v0.1.0
[M+Na]+152.43518
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Aspartate carbamoyltransferase catalytic chain
Kind
Protein
Organism
Shigella flexneri
Pharmacological action
Unknown
General Function
Aspartate carbamoyltransferase activity
Specific Function
Not Available
Gene Name
pyrB
Uniprot ID
P0A789
Uniprot Name
Aspartate carbamoyltransferase catalytic chain
Molecular Weight
34427.02 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Details2. CAD protein
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
This protein is a "fusion" protein encoding four enzymatic activities of the pyrimidine pathway (GATase, CPSase, ATCase and DHOase).
Gene Name
CAD
Uniprot ID
P27708
Uniprot Name
CAD protein
Molecular Weight
242981.73 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at February 21, 2021 18:51